{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:41Z","timestamp":1792012901273,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.anpedi.2019.05.010","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T09:17:55Z","timestamp":1572859075000},"page":"124-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Metotrexato en artritis idiop\u00e1tica juvenil: efectos adversos y factores asociados"],"prefix":"10.1016","volume":"92","author":[{"given":"Estefan\u00eda","family":"Barral Mena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Garc\u00eda C\u00e1rdaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Canet Tarr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Enr\u00edquez Merayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Cruz Utrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"de Inocencio Arocena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpedi.2019.05.010_bib0150","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-018-1571-6","article-title":"Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: Results from the Nordic cohort study","volume":"20","author":"Rypdal","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0160","doi-asserted-by":"crossref","first-page":"177.e1","DOI":"10.1016\/j.anpedi.2015.05.005","article-title":"Recomendaciones para el uso de metotrexato en pacientes con artritis idiop\u00e1tica juvenil","volume":"84","author":"Calvo","year":"2016","journal-title":"An Pediatr Barc."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: Advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara","year":"2018","journal-title":"Pediatr Rheumatol Online J."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12969-016-0099-z","article-title":"Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration","volume":"14","author":"Fr\u00e1\u0148ov\u00e1","year":"2016","journal-title":"Pediatr Rheumatol Online J."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0175","first-page":"299","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: A systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"Bio Drugs."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0180","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00296-010-1774-x","article-title":"Adherence to methotrexate in juvenile idiopathic arthritis","volume":"32","author":"Pelajo","year":"2012","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0185","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0190","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0195","first-page":"1830","article-title":"Methotrexate in juvenile idiopathic arthritis: Answers and questions","volume":"27","author":"Ravelli","year":"2000","journal-title":"J Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0200","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/ard.2007.075895","article-title":"Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis","volume":"67","author":"C\u00e9spedes-Cruz","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0210","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3899\/jrheum.090826","article-title":"Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: Comparison of 2 initial dosing regimens","volume":"37","author":"Becker","year":"2010","journal-title":"J Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0215","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/art.30367","article-title":"High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score","volume":"63","author":"Bulatovi\u0107","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0220","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/acr.21697","article-title":"Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: An observational study with patients from the German Methotrexate Registry","volume":"64","author":"Klein","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0225","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3899\/jrheum.090482","article-title":"Monitoring methotrexate toxicity in juvenile idiopathic arthritis","volume":"36","author":"Kocharla","year":"2009","journal-title":"J Rheumatol."},{"issue":"Suppl 2","key":"10.1016\/j.anpedi.2019.05.010_bib0230","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/annrheumdis-2015-eular.5173","article-title":"How tolerable is methotrexate in the long-term use in Juvenile Idiopathic Arthritis (JIA)?","volume":"74","author":"Minden","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0235","first-page":"2501","article-title":"Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis","volume":"31","author":"Ortiz-Alvarez","year":"2004","journal-title":"J Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0240","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10067-013-2389-x","article-title":"Methotrexate-induced nausea and vomiting in adolescent and young adult patients","volume":"33","author":"Patil","year":"2014","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0245","first-page":"148","article-title":"Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: A cross-sectional, observational study","volume":"34","author":"van Dijkhuizen","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0250","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1546-0096-11-23","article-title":"Mothers\u2019 reports of the difficulties that their children experience in taking methotrexate for juvenile idiopathic arthritis and how these impact on quality of life","volume":"11","author":"Mulligan","year":"2013","journal-title":"Pediatr Rheumatol Online J."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0255","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-016-1109-8","article-title":"The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis","volume":"18","author":"Beukelman","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0260","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1546-0096-12-54","article-title":"Procedural pain and patient-reported side effects with weekly injections of subcutaneous methotrexate in children with rheumatic disorders","volume":"12","author":"Bechard","year":"2014","journal-title":"Pediatr Rheumatol Online J."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0265","first-page":"181","article-title":"Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group","volume":"16","author":"Ravelli","year":"1998","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0270","first-page":"179","article-title":"The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate","volume":"31","author":"Alsufyani","year":"2004","journal-title":"J Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0275","first-page":"625","article-title":"Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis","volume":"17","author":"Ravelli","year":"1999","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0280","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1546-0096-12-51","article-title":"Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: A systematic literature review","volume":"12","author":"Van Dijkhuizen","year":"2014","journal-title":"Pediatr Rheumatol Online J."},{"key":"10.1016\/j.anpedi.2019.05.010_bib0285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12969-018-0229-x","article-title":"Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients","volume":"16","author":"Schoemaker","year":"2018","journal-title":"Pediatr Rheumatol Online J."},{"issue":"Suppl 1","key":"10.1016\/j.anpedi.2019.05.010_bib0290","doi-asserted-by":"crossref","first-page":"O23","DOI":"10.1186\/1546-0096-9-S1-O23","article-title":"Treatment of methotrexate (MTX) intolerance: Behavioural therapy, versus switch to parenteral MTX versus oral MTX","volume":"9","author":"Verkaaik","year":"2011","journal-title":"Pediatric Rheumatology"}],"container-title":["Anales de Pediatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403319302012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403319302012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:49:11Z","timestamp":1761662951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1695403319302012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1695403319302012"],"URL":"https:\/\/doi.org\/10.1016\/j.anpedi.2019.05.010","relation":{},"ISSN":["1695-4033"],"issn-type":[{"value":"1695-4033","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metotrexato en artritis idiop\u00e1tica juvenil: efectos adversos y factores asociados","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2019.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}